1. Record Nr. UNINA9910457701703321

Autore	Evans Diana <1947->
Titolo	Greasing the wheels : using pork barrel projects to build majority coalitions in Congress / / Diana Evans [[electronic resource]]
Pubbl/distr/stampa	Cambridge : , : Cambridge University Press, , 2004
ISBN	1-107-16155-X 1-280-54055-9 0-511-21549-5 0-511-21728-5 0-511-21191-0 0-511-31587-2 0-511-61714-3 0-511-21368-9
Descrizione fisica	1 online resource (xii, 267 pages) : digital, PDF file(s)
Disciplina	328.73/0775
Soggetti	Coalitions United States Politics and government
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Title from publisher's bibliographic system (viewed on 05 Oct 2015).
Nota di bibliografia	Includes bibliographical references (p. 245-258) and index.
Nota di contenuto	Pork barrel politics and general interest legislation -- Who calls the shots? The allocation of pork barrel projects -- Highway demonstration projects and voting on the federal highway program -- Presidential bargaining with congress: the NAFTA bazaar -- Pork barreling in the Senate: do both parties do it?
Sommario/riassunto	Pork barrel projects would surely rank near the top of most observers' lists of Congress's most widely despised products. Yet, political leaders in Congress and the President often trade pork for votes to pass legislation that serves broad national purposes, giving members of Congress pork barrel projects in return for their votes on general interest legislation. It is a practice that succeeds at a cost, but it is a cost that many political leaders are willing to pay in order to enact the broader public policies that they favor. There is an irony in this: pork barrel benefits, the most reviled of Congress's legislative products, are used by policy coalition leaders to produce the type of policy that is

	most admired - general interest legislation. This book makes the case that buying votes with pork is one way in which Congress solves its well-known collective action problem.

2.

Record Nr.	UNINA9910298290903321
Titolo	Lyophilized Biologics and Vaccines : Modality-Based Approaches / / edited by Dushyant Varshney, Manmohan Singh
Pubbl/distr/stampa	New York, NY : , : Springer New York : , : Imprint : Springer, , 2015
ISBN	1-4939-2383-8
Edizione	[1st ed. 2015.]
Descrizione fisica	1 online resource (399 p.)
Disciplina	571967 610 615.19 615372 616.0798
Soggetti	Vaccines Immunoglobulins Pharmaceutical technology Vaccine Antibodies Pharmaceutical Sciences/Technology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index at the end of each chapters.
Nota di contenuto	Preface -- Part I – Lyophilization History and Fundamentals -- History of Lyophilization -- Heterogeneity of protein environments in frozen solutions and in the dried state -- Advance understanding of buffer behavior during lyophilization -- Advances in Instrumental Analysis Applied to the Development of Lyophilization Cycles -- New Developments in Controlled Nucleation: Commercializing VERISEQ® Nucleation technology -- Part II – Lyophilized Biologics and Vaccines – Modality Considerations -- Lyophilized Biologics -- Lyophilization of

Therapeutic Proteins in Vials - Process Scale-up and Advances in Quality by Design -- Advances in Process Analytical Technology in Freeze Drying -- Process Scale-up and Optimization of Lyophilized Vaccine Products -- Stabilization of Plasmid DNA and Lipid-based Therapeutics as Dehydrated Formulations -- Part III – Advances in Alternate Drying -- Alternatives to Vial Lyophilization -- Spray Drying of Biopharmaceuticals -- Current Trends and Advances in Bulk Crystallization and Freeze Drying of Biopharmaceuticals -- Case Studies and Examples of Biopharmaceutical Modalities -- Processed by Bulk Crystallization or Bulk Freeze Drying -- Part IV– Regulatory, Packaging and Technology Transfer Considerations -- Lyophilization of Biologics - An FDA Perspective -- Recent Trends in Lyophilized Delivery Devices and Packaging -- Lyophilization Technology Transfer towards Product Launch.

Sommario/riassunto

This book provides a detailed account of the most recent developments, challenges and solutions to seamlessly advance and launch lyophilized biologics or vaccine products, based on diverse modalities, ranging from antibodies (e.g., monoclonal, fusion), complex biologics (e.g., antibody drug conjugates, PEGylated proteins) and vaccines (e.g., recombinant protein based). The authors adeptly guide you through everything you need to know, from biophysical and chemical stability considerations of proteins, to critical assessment during process scale-up, technology transfer, packaging, alternate drying and device selection for a successful process validation, regulatory submission and launch of a stable, safe and effective product. Lyophilized Biologics and Vaccines: Modality-Based Approaches serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch: Provides recent understanding of heterogeneity of protein environment in frozen systems, buffer stabilization, instrumental analysis and controlled ice nucleation technology Details product development strategies based on diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics Recent updates on quality-by-design and process analytical technology approaches, illustrated by case studies and FDA perspective Provides the latest account of alternate drying technologies including spray drying and bulk freeze-drying Chapters are written by one or more world-renowned leading authorities from academia, industry or regulatory agencies, whose expertise cover lyophilization of the diverse modalities of biopharmaceuticals. Their contributions are based on the exhaustive review of literature coupled with excellent hands-on experiences in laboratory or GMP setup, making this an exceptional guide to all stages of lyophilized or dehydrated product development and commercial manufacturing. Dushyant B. Varshney, Ph.D., has made significant contributions in manufacturing science and technology, due diligence, tech transfer, product and process development (including lyophilization), quality-by-design and process analytical technologies for biologics, vaccines and small molecules. He is currently a Director of Manufacturing Assessment, MS&T at Hospira Inc. Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He is currently the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC.